High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) ...

Sana Biotechnology advances engineered cell therapies as nasdaq 100 composition discussions highlight innovative ...

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating the efficacy and safety profile of tobevibart, an investigational ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. Congress should invest ...

Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.

Yarrowia lipolytica has emerged as a versatile yeast platform for biotechnological applications ranging from biofuel synthesis to high-value chemical production. Its oleaginous nature and robust ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating the efficacy and safety profile of ...